Wedbush Reaffirms Neutral Rating for Ikena Oncology (NASDAQ:IKNA)

Wedbush reiterated their neutral rating on shares of Ikena Oncology (NASDAQ:IKNA) in a research report sent to investors on Thursday morning,RTT News reports. Wedbush currently has a $2.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Ikena Oncology in a research report on Monday, August 12th.

Ikena Oncology Stock Up 4.1 %

Shares of Ikena Oncology stock opened at $1.76 on Thursday. Ikena Oncology has a 1 year low of $1.02 and a 1 year high of $3.92. The stock has a fifty day moving average price of $1.70 and a 200-day moving average price of $1.64.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.08. As a group, equities research analysts expect that Ikena Oncology will post -1.03 EPS for the current year.

Institutional Investors Weigh In On Ikena Oncology

Several large investors have recently added to or reduced their stakes in IKNA. Acadian Asset Management LLC increased its holdings in Ikena Oncology by 1,201.8% in the 1st quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock worth $400,000 after acquiring an additional 261,060 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Ikena Oncology by 813.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after purchasing an additional 457,245 shares during the period. Deuterium Capital Management LLC bought a new position in Ikena Oncology in the 2nd quarter worth about $133,000. BBR Partners LLC bought a new position in Ikena Oncology in the 2nd quarter worth about $33,000. Finally, JBF Capital Inc. bought a new position in Ikena Oncology in the 2nd quarter worth about $120,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.